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Volume 50, Number 1 Abstracts 235an urban academic medical center and randomized 156 patients to super-
vised treadmill exercise, lower extremity resistance training, or to a control
group. The main outcome measures were a 6-minute walk performance and
a short physical performance battery. Secondary outcomes were brachial
artery flow–mediated dilatation, treadmill walking performance, scores on
the Walking Impairment Questionnaire, and scores on the Short Form
35-Item Health Survey physical functioning (SF-36PF) questionnaire.
With respect to control groups, patients in the 6-minute walk who
underwent supervised exercise training improved walking distance by
35.9 m (P  .001) and patients who received resistance training improved
walking distance by 12.4 m (P  .24). Neither the treadmill group nor the
resistance training group improved short form physical battery scores.
Brachial artery flow–mediated dilatation improved by 1.53% in the treadmill
group (P  .02) compared with controls. Compared with controls, the
treadmill group had greater increases in maximal treadmill walking time
(3.44 minutes, P  .001), walking impairment distance score (10.7, P 
.02), and SF-36PF score (7.5, P  .02). The resistance training group had
greater increases in maximal treadmill walking time (1.9 minutes, P .009),
walking impairment scores for distance (6.92, P .02), stair climbing (10.4,
P  .03), and SF-36PF score (7.5, P  .04) than controls.
Comment: This study indicates that patients with PAD without symp-
toms of claudication should be treated with supervised treadmill exercise to
improve function and, as suggested by improvements in brachial artery
flow–mediated dilatation, improve underlying endothelial dysfunction that
may contribute to atherosclerosis. Supervised treadmill exercise produces
greater increases in 6-minute walk performance than resistance training.
Resistance training, however, also produced potential clinical improvements
on quality of life measures and stair climbing ability. It is becoming increas-
ingly clear that patients with PAD, whether or not they are symptomatic,
should be treated essentially as low-level, deconditioned athletes. Benefits
can be measured from both resistance and nonresistance training that may
over time reduce the accelerated functional decline associated with PAD.
Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardio-
vascular Disease: The Framingham Offspring Study
Frankel DS, Meigs JB, Massaro JM, et al. Circulation 2008;118:2533-9.Conclusion: Increased levels of von Willebrand factor (vWF) are
associated with the risk of cardiovascular disease in patients with insulin
resistance or type 2 diabetes mellitus.
Summary: vWF is a large glycoprotein produced by endothelial cells
that participates in the initial steps of thrombus formation by mediating
platelet adhesion to injured endothelium. Because it interacts with endothe-
lium, vWF may be a biomarker of endothelial damage. Because vWF is also
known to be associated with insulin resistance and type 2 diabetes, vWFmay
be a risk factor for cardiovascular disease and may have increased significance
in patients with insulin resistance or type 2 diabetes.
The authors tested the hypothesis that vWF predicted the incidence
cardiovascular disease in 3799 Framingham Offspring Study participants,
focusing on those with insulin resistance or type 2 diabetes. The Framing-
ham Offspring Study is a prospective observational study of cardiovascular
disease and risk factors. It began in 1971 by enrolling children of the original
Framingham Heart Study cohort and the children’s spouses. During 11
years of follow-up, cardiovascular disease developed in 351 participants.
Adjusting for age, sex, blood pressure, smoking, body mass index, and
high-density lipoprotein levels as well as treatment with aspirin, insulin,
antihypertensives, and lipid-lowering medications, the hazard ratio (HR) for
cardiovascular disease was 0.94 in the second quartile of vWF distribution,
0.98 in the third quartile, and 1.32 in the highest quartile, using the lowest
quartile as the reference (P .04 for trend). Adjusting for type 2 diabetes or
insulin resistance attenuated the association (HRs for top quartile 1.28, and
1.21, respectively). The model was also stratified for diabetes and insulin
resistance distribution (top quartile vs lower three quartiles). vWF was
associated with cardiovascular disease among participants with diabetes
mellitus (HR for top quartile relative to bottom, 1.47; P  .04) but not
among nondiabetic participants (HR, 1.15; P .5). vWFwas also associated
with cardiovascular disease among those with insulin resistance (HR, 1.5;
P .01) but not among those whowere insulin sensitive (HR, 1.02; P .9).
Comment: The data suggest vWF may be a risk factor unique in
patients with type 2 diabetesmellitus or insulin resistance. Although diabetes
mellitus and insulin resistance are clear risk factors for cardiovascular disease,
patients with these risk factors have varying severities of clinical manifesta-
tions of atherosclerosis. This study offers the possibility of additional risk
stratification among these patients based on levels of vWF.
